Q-omics provides the consensus-scored INTS4P1 profile across patient tissues and cancer cell-line models. INTS4P1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, INTS4P1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, INTS4P1 RNA expression shows 16,158 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where INTS4P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INTS4P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INTS4P1 survival associations across molecular data types. INTS4P1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INTS4P1 RNA expression–survival associations across cancer types. High INTS4P1 expression shows unfavorable associations in KIRC, LGG, CHOL and ACC, but favorable associations in PAAD and READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for INTS4P1 RNA expression.
This table summarizes INTS4P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for INTS4P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INTS4P1 shows higher tumor expression in KIRC, LIHC, LUAD, CHOL, KIRP and STAD. The KIRC box plot shows higher INTS4P1 RNA expression in tumor versus normal tissue (log2 FC = +0.188, t-test p < 0.001).
This table shows molecular features associated with INTS4P1 in patient tissues and cancer cell lines. In patient samples, INTS4P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, INTS4P1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS.
